Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MYC006
MIFTS: 66

Mycosis Fungoides

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mycosis Fungoides

About this section

MalaCards integrated aliases for Mycosis Fungoides:

Name: Mycosis Fungoides 56 12 74 52 25 36 54 43 15 37 17 71 32
Mycosis Fungoides Lymphoma 12 74
Alibert-Bazin Syndrome 52 25
Granuloma Fungoides 52 25
Mycosis Fungoides, Alibert-Bazin Type 58
Classic Mycosis Fungoides 58

Characteristics:

Orphanet epidemiological data:

58
classic mycosis fungoides
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

OMIM:

56
Inheritance:
familial aggregation without simple mendelian pattern


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare skin diseases
Rare haematological diseases


Sources

Summaries for Mycosis Fungoides

About this section
Genetics Home Reference : 25 Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. Although the skin is involved, the skin cells themselves are not cancerous. Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified. Mycosis fungoides may progress slowly through several stages, although not all people with the condition progress through all stages. Most affected individuals initially develop skin lesions called patches, which are flat, scaly, pink or red areas on the skin that can be itchy. Cancerous T cells, which cause the formation of patches, are found in these lesions. The skin cells themselves are not cancerous; the skin problems result when cancerous T cells move from the blood into the skin. Patches are most commonly found on the lower abdomen, upper thighs, buttocks, and breasts. They can disappear and reappear or remain stable over time. In some affected individuals, patches progress to plaques, the next stage of mycosis fungoides. Plaques are raised lesions that are usually reddish, purplish, or brownish in color and itchy. Plaques commonly occur in the same body regions as patches. While some plaques arise from patches, others develop on their own, and an affected person can have both patches and plaques simultaneously. As with patches, cancerous T cells are found in plaques. Plaques can remain stable or can develop into tumors. Not everyone with patches or plaques develops tumors. The tumors in mycosis fungoides, which are composed of cancerous T cells, are raised nodules that are thicker and deeper than plaques. They can arise from patches or plaques or occur on their own. Mycosis fungoides was so named because the tumors can resemble mushrooms, a type of fungus. Common locations for tumor development include the upper thighs and groin, breasts, armpits, and the crook of the elbow. Open sores may develop on the tumors, often leading to infection. Although rare, the cancerous T cells can spread to other organs, including the lymph nodes, spleen, liver, and lungs. Spread to other organs can occur in any stage of mycosis fungoides but is most common in the tumor stage. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer.

MalaCards based summary : Mycosis Fungoides, also known as mycosis fungoides lymphoma, is related to lymphomatoid papulosis and cutaneous t cell lymphoma. An important gene associated with Mycosis Fungoides is CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Methoxsalen and Clorazepate Dipotassium have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and b cells, and related phenotypes are pruritus and dry skin

NIH Rare Diseases : 52 Mycosis fungoides is a disease in which T-cell lymphocytes (a type of white blood cell ) become malignant (cancerous) and affect the skin. This condition is one of the most common types of T-cell lymphoma . Mycosis fungoides is characterized by a scaly, red rash that develops on the skin, particularly on areas that are not usually exposed to the sun. The rash may last for months or years without causing any symptoms. Over time, a thin, reddened, eczema-like rash may develop, followed by thickened, red patches of skin. Finally, tumors form which may develop into ulcers and become infected. Mycosis fungoides is difficult to cure. Treatment is usually palliative, with the intention of relieving symptoms and improving the quality of life.

OMIM : 56 Mycosis fungoides is a malignant T-cell lymphoma of the skin, first reported (and named) by Alibert (1835). Sezary syndrome is a leukemic variant of mycosis fungoides defined by erythroderma with greater than 80% of the skin showing redness, adenopathy and greater than 1,000 circulating Sezary cells/microliter with a CD4+CD26- or CD4+CD7- phenotype. Sezary cells have a type 2 helper T cell cytokine profile. Sezary syndrome has a median overall survival time of only 2.4 years in patients with Sezary cells at a density of greater than 10,000 cells/microliter or 5.4 years in patients with 1,000-10,000 Sezary cells/microliter. Mycosis fungoides and Sezary syndrome are the most common cutaneous T-cell lymphomas. Sezary syndrome can arise de novo or can appear following years of chronic mycosis fungoides. Both are thought to arise from clonal expansion of CD4+ helper T cells responding to chronic antigen stimulation (summary by Wang et al., 2015). (254400)

KEGG : 36 Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphomas (CTCL), which are a heterogeneous group of malignancies derived from skin-homing T cells. MF presents in the skin with erythematous patches, plaques, and less frequently, tumours. Although the aetiologies of MF are unknown, important insights have been gained in the immunological and genetic perturbations that are associated with these diseases. Mutations in the p53, p15, p16, JunB, and PTEN genes generally occur in later-stage disease. Loss of normal apoptotic T-cell pathways has also been reported. Apoptosis is partly mediated by death receptors, notably Fas, which is part of the tumor necrosis factor family of receptors. Decreased and/or defective Fas expression by neoplastic T cells has been associated with advanced/aggressive disease and impaired Fas-mediated apoptosis.

Wikipedia : 74 Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form... more...

Sources

Related Diseases for Mycosis Fungoides

About this section

Diseases related to Mycosis Fungoides via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 563)
# Related Disease Score Top Affiliating Genes
1 lymphomatoid papulosis 33.5 TNFRSF8 TIA1
2 cutaneous t cell lymphoma 32.6 TNFRSF8 TIA1 ITGAE IL2RB IL2RA IL2
3 parapsoriasis 32.4 TNFRSF8 CD7
4 follicular mucinosis 32.3 TNFRSF8 IFNA2 CD7
5 sezary's disease 32.3 TNFRSF8 TNFRSF1B IL2RB IL2RA IL2 IFNA1
6 primary cutaneous t-cell lymphoma 32.1 TNFRSF8 IL2RA
7 pityriasis lichenoides 32.0 TNFRSF8 CD7
8 t-cell leukemia 31.9 IL2RB IL2RA IL2 CD7 CCR4
9 contact dermatitis 31.8 IL2 CXCR3 CCR10 CCL22 CCL17
10 lymphoproliferative syndrome 31.8 IL2RA IL2 IFNA2 CTLA4
11 dermatitis 31.7 IL2 CXCR3 CXCL9 CTLA4 CCR4 CCR10
12 hypereosinophilic syndrome 31.6 IL2RA IL2 IFNA2 IFNA1 CCL17
13 exanthem 31.6 TNFRSF1B IL2 CTLA4
14 anaplastic large cell lymphoma 31.6 TNFRSF8 TIA1 IL2RA CXCR3 CCR4 CCL17
15 t-cell non-hodgkin lymphoma 31.6 CCR4 CCL17
16 lichen planus 31.5 IL2 CXCR3 CXCL9 CD1A
17 peripheral t-cell lymphoma 31.5 TNFRSF8 TIA1 IL2RB IL2 CXCR3 CCR4
18 t-cell lymphoma, subcutaneous panniculitis-like 31.5 TNFRSF8 TIA1 CD7
19 allergic hypersensitivity disease 31.5 IL2 CTLA4 CCR4 CCL22 CCL17
20 lymphoma, hodgkin, classic 31.5 TNFRSF8 TIA1 IL2RA IL2 CCR4 CCL17
21 allergic contact dermatitis 31.5 CXCR3 CCR4 CCR10 CCL22 CCL17
22 erythema multiforme 31.4 IL2 CXCR3 CCL17
23 granuloma annulare 31.4 TNFRSF1B CD1A
24 spongiotic dermatitis 31.4 CD7 CD1A
25 herpes zoster 31.4 TNFRSF1B IL2 IFNA2 IFNA1
26 adult t-cell leukemia 31.4 TNFRSF8 IL2RA IL2 CTLA4 CD7 CCR4
27 alopecia areata 31.3 IL2RA IL2 CXCR3 CXCL9 CTLA4
28 t-cell adult acute lymphocytic leukemia 31.2 TNFRSF8 TIA1 IL2RA IL2 CD7
29 stevens-johnson syndrome/toxic epidermal necrolysis 31.2 IL2 CXCR3 CCL22 CCL17
30 psoriasis 31.2 TNFRSF1B IL2RA IL2 CXCR3 CXCL9 CTLA4
31 sarcoidosis 1 31.2 TNFRSF1B IL2RB IL2RA IL2 CXCR3 CXCL9
32 composite lymphoma 31.2 TNFRSF8 TIA1
33 angioimmunoblastic t-cell lymphoma 31.1 TNFRSF8 TIA1 IL2RA CD28
34 cutaneous lupus erythematosus 31.1 IFNA1 CXCR3 CCL17
35 acute graft versus host disease 31.1 IL2RB IL2RA IL2
36 diphtheria 31.0 IL2RB IL2RA IL2
37 tropical spastic paraparesis 31.0 IL2RB IL2RA IL2 CXCR3
38 lymphopenia 31.0 IL2RB IL2RA IL2 CTLA4 CD28 CCL22
39 pityriasis lichenoides et varioliformis acuta 31.0 TNFRSF8 CD7
40 lymphomatoid granulomatosis 30.9 TIA1 IFNA2 IFNA1 CXCL9
41 cryoglobulinemia, familial mixed 30.9 IFNA2 IFNA1
42 cryoglobulinemia 30.9 IFNA2 IFNA1 CXCR3
43 skin sarcoidosis 30.9 TNFRSF1B CTLA4 CD1A
44 lymphadenitis 30.8 IL2RB IL2RA CXCR3 CXCL9 CCL22
45 myeloma, multiple 30.8 TNFRSF8 IL2 IFNA1 CTLA4 CD28
46 uveitis 30.8 TNFRSF1B IL2RA IL2 IFNA2 CXCR3 CTLA4
47 pulmonary sarcoidosis 30.8 IL2RA IL2 CXCR3 CXCL9
48 thyroiditis 30.8 IL2 IFNA1 CTLA4
49 hairy cell leukemia 30.7 ITGAE IL2RB IL2RA IL2 IFNA2 IFNA1
50 leukemia, chronic lymphocytic 30.7 TNFRSF8 ITGAE IL2RA IL2 IFNA1 CXCR3

Graphical network of the top 20 diseases related to Mycosis Fungoides:



Diseases related to Mycosis Fungoides
Sources

Symptoms & Phenotypes for Mycosis Fungoides

About this section

Human phenotypes related to Mycosis Fungoides:

58 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000989
2 dry skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000958
3 skin rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0000988
4 erythema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010783
5 neoplasm of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0008069
6 eczema 58 31 hallmark (90%) Very frequent (99-80%) HP:0000964
7 skin plaque 58 31 hallmark (90%) Very frequent (99-80%) HP:0200035
8 abnormal lymphocyte morphology 31 hallmark (90%) HP:0004332
9 alopecia 58 31 frequent (33%) Frequent (79-30%) HP:0001596
10 hypopigmented skin patches 58 31 frequent (33%) Frequent (79-30%) HP:0001053
11 irregular hyperpigmentation 58 31 frequent (33%) Frequent (79-30%) HP:0007400
12 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
13 poikiloderma 58 31 frequent (33%) Frequent (79-30%) HP:0001029
14 cutaneous t-cell lymphoma 58 31 frequent (33%) Frequent (79-30%) HP:0012192
15 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
16 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
17 abnormality of the nail 58 31 occasional (7.5%) Occasional (29-5%) HP:0001597
18 hyperkeratosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000962
19 edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0000969
20 skin ulcer 58 31 occasional (7.5%) Occasional (29-5%) HP:0200042
21 abnormality of bone marrow cell morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0005561
22 abnormal eyelid morphology 31 occasional (7.5%) HP:0000492
23 lymphoma 58 31 Very frequent (99-80%) HP:0002665
24 psoriasiform dermatitis 31 HP:0003765
25 abnormality of the eyelid 58 Occasional (29-5%)
26 abnormality of lymphocytes 58 Very frequent (99-80%)

Symptoms via clinical synopsis from OMIM:

56
Skin Nails Hair Skin:
pruritus
psoriasiform dermatitis
erythema
malignant t-cell skin lymphoma
skin scaling
more
Immunology:
lymphadenopathy

Clinical features from OMIM:

254400

MGI Mouse Phenotypes related to Mycosis Fungoides:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.85 CCR10 CD28 CD7 CTLA4 DPP4 IL2
2 hematopoietic system MP:0005397 9.8 CCL17 CCR10 CCR4 CD28 CD7 CTLA4
3 immune system MP:0005387 9.5 CCL17 CCL22 CCR10 CCR4 CD28 CD7
Sources

Drugs & Therapeutics for Mycosis Fungoides

About this section

Drugs for Mycosis Fungoides (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 318)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methoxsalen Approved Phase 4 298-81-7 4114
2 Clorazepate Dipotassium Phase 4
3 Thymoglobulin Phase 4
4 Photosensitizing Agents Phase 4
5 Interferon alpha-2 Phase 4
6 interferons Phase 4
7 Interferon-alpha Phase 4
8
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
9 Orange Approved Phase 3
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
12
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
13
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
14
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
15
Ofloxacin Approved Phase 3 82419-36-1 4583
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
18
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
19
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
20
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
21
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
22
Acyclovir Approved Phase 3 59277-89-3 2022
23
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
24
Captopril Approved Phase 3 62571-86-2 44093
25
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
26
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
27
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
28
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
29
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
30
Polyestradiol phosphate Approved Phase 3 28014-46-2
31
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
32
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
33
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
34 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
35
Hypericin Investigational Phase 3 548-04-9 5281051
36 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
37 Anesthetics, Dissociative Phase 3
38 Antiviral Agents Phase 3
39 Etoposide phosphate Phase 2, Phase 3
40 Antiparasitic Agents Phase 3
41 Antiprotozoal Agents Phase 3
42 Central Nervous System Depressants Phase 3
43 Amotosalen Phase 3
44 Ficusin Phase 3
45 Furocoumarins Phase 3
46 Narcotics Phase 3
47 Hematinics Phase 3
48 Epoetin alfa Phase 3 113427-24-0
49 Cytochrome P-450 Enzyme Inhibitors Phase 3
50 Anesthetics Phase 3

Interventional clinical trials:

(show top 50) (show all 409)
# Name Status NCT ID Phase Drugs
1 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Unknown status NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
2 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
3 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
4 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
5 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti－human Thymoglobulin;Placebo
6 Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa. Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
7 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
9 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
10 A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
11 A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
12 A Multi-center, Randomized Study on Oral 8-methoxypsoralen Plus UVA With or Without Maintenance Therapy in Mycosis Fungoides EORTC/ISCL Stage IA to IIB Completed NCT01686594 Phase 3 8-methoxypsoralen
13 A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor Completed NCT00490776 Phase 2, Phase 3 LBH589
14 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
15 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
16 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
17 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
18 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
19 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
20 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
21 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
22 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
23 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
24 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
25 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
26 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
27 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
28 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
29 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
30 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
31 Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides: A Randomized Controlled Trial Recruiting NCT03454945 Phase 3 Vibramycin
32 A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
33 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma Active, not recruiting NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
34 Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
35 A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma Terminated NCT01098656 Phase 3 lenalidomide
36 A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3 bexarotene;methoxypsoralen
37 Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
38 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
39 Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study. Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
40 Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
41 PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
42 A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
43 A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma Unknown status NCT02213861 Phase 2 SHAPE
44 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
45 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Unknown status NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
46 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
47 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
48 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
49 A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies Completed NCT00038025 Phase 2 Deoxycoformycin (DCF)
50 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron

Search NIH Clinical Center for Mycosis Fungoides

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyclophosphamide
Etoposide
etoposide phosphate
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Mechlorethamine
Mechlorethamine hydrochloride
Methotrexate
Methotrexate Sodium
Methoxsalen
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Uracil Mustard
Vinblastine
Vinblastine Sulfate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mycosis Fungoides cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Mycosis Fungoides:
Hematopoietic stem cells for treatment of hematologic malignancies
Blood stem cell transplantation for hematological diseases
Embryonic/Adult Cultured Cells Related to Mycosis Fungoides:
Bone marrow-derived hematopoietic stem cells
Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: mycosis fungoides

Sources

Genetic Tests for Mycosis Fungoides

About this section
Sources

Anatomical Context for Mycosis Fungoides

About this section

MalaCards organs/tissues related to Mycosis Fungoides:

40
T Cells, Skin, B Cells, Bone, Bone Marrow, Lymph Node, Liver
Sources

Publications for Mycosis Fungoides

About this section

Articles related to Mycosis Fungoides:

(show top 50) (show all 5921)
# Title Authors PMID Year
1
Lymphomas and leukemias in the relatives of patients with mycosis fungoides. 61 56
7055783 1982
2
Familial mycosis fungoides revisited. 61 56
7425665 1980
3
Mycosis fungoides of prolonged duration in siblings. 61 56
5246760 1968
4
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. 56
26551667 2015
5
Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. 56
26551670 2015
6
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. 54 61
20212249 2010
7
Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. 54 61
19242508 2009
8
Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. 54 61
19289586 2009
9
Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic simulants. 54 61
19220628 2009
10
Lesional skin chemokine CTACK/CCL27 expression in mycosis fungoides and disease control by IFN-alpha and PUVA therapy. 54 61
19956431 2009
11
Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. 54 61
19239991 2008
12
The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. 54 61
18644018 2008
13
The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome. 54 61
18089499 2008
14
Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. 54 61
17975162 2007
15
Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. 54 61
17367611 2007
16
CD13 and TCR clone: markers of early mycosis fungoides. 54 61
17340024 2007
17
Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay. 54 61
16931956 2006
18
Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias. 54 61
16741518 2006
19
Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. 54 61
16859899 2006
20
CXCR3 and CCR4 double positive tumor cells in granulomatous mycosis fungoides. 54 61
16713487 2006
21
Immunogold detection of CD3 and CD4 antigens in patients with Mycosis fungoides. 54 61
17013537 2006
22
Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome. 54 61
16197392 2005
23
CCR10 is expressed in cutaneous T-cell lymphoma. 54 61
15700309 2005
24
Treatment with IFN-gamma increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides. 54 61
15927812 2005
25
Concurrent mycosis fungoides and precursor B cell lymphoblastic lymphoma in a 6-year-old child. 54 61
15660892 2005
26
Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. 54 61
15328201 2004
27
Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. 54 61
14708605 2003
28
Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. 54 61
12393570 2003
29
Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. 54 61
12522366 2003
30
Clusterin expression in malignant lymphomas: a survey of 266 cases. 54 61
12429802 2002
31
Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. 54 61
12209749 2002
32
Relative content of cytokines in different tissues in mycosis fungoides. 54 61
12459845 2002
33
Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. 54 61
11874489 2002
34
Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). 54 61
11908715 2002
35
Cytokine profile of patients with mycosis fungoides and the immunomodulatory effect of AS101. 54 61
11720171 2001
36
Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. 54 61
11453809 2001
37
Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. 54 61
11392886 2001
38
Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). 54 61
11359391 2001
39
The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. 54 61
11242798 2001
40
Gab2 is phosphorylated on tyrosine upon interleukin-2/interleukin-15 stimulation in mycosis-fungoides-derived tumor T cells and associates inducibly with SHP-2 and Stat5a. 54 61
11340297 2001
41
Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective. 54 61
11707858 2000
42
IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. 54 61
10949545 2000
43
Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. 54 61
10887135 2000
44
Lack of membrane expression of interleukin-2 receptor alpha chain (CD25) in mycosis fungoides: application of laser scanning cytometry for phenotyping of skin infiltrating lymphocytes. 54 61
10777356 2000
45
Macrophage-derived chemokine production by activated human T cells in vitro and in vivo: preferential association with the production of type 2 cytokines. 54 61
10602042 2000
46
Interferon-alpha-associated development of bullous lesions in mycosis fungoides. 54 61
10681616 2000
47
Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. 54 61
10504456 1999
48
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). 54 61
10233762 1999
49
Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. 54 61
10374878 1999
50
Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. 54 61
10233858 1999
Sources

Variations for Mycosis Fungoides

About this section

Cosmic variations for Mycosis Fungoides:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87675933 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.12655C>T p.Q4219* 12:49032050-49032050 0
Sources

Expression for Mycosis Fungoides

About this section
Search GEO for disease gene expression data for Mycosis Fungoides.
Sources

Pathways for Mycosis Fungoides

About this section

Pathways related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.98 TNFRSF8 TNFRSF1B IL2RB IL2RA IL2 IFNA2
2
ERK Signaling 63
Show member pathways
 13.74 TNFRSF8 TNFRSF1B ITGAE IL2RB IL2RA IL2
3
PEDF Induced Signaling 63
Show member pathways
 13.51 TNFRSF8 TNFRSF1B IL2RB IL2RA IL2 IFNA2
4
TGF-Beta Pathway 63
Show member pathways
 13.49 TNFRSF1B ITGAE IL2RB IL2RA IL2 IFNA2
5
Integrin Pathway 63
Show member pathways
 13.34 ITGAE CXCR3 CXCL9 CCR4 CCR10 CCL22
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.3 TNFRSF8 TNFRSF1B IL2RB IL2RA IL2 IFNA2
7
Akt Signaling 63
Show member pathways
 13.12 TNFRSF8 TNFRSF1B ITGAE IL2RB IL2RA IL2
8
PAK Pathway 63
Show member pathways
 13.1 TNFRSF8 TNFRSF1B IL2RB IL2RA IL2 CXCR3
9
CCR5 Pathway in Macrophages 63
Show member pathways
 12.84 CXCR3 CXCL9 CCR4 CCR10 CCL22 CCL17
10
Allograft rejection 1 36
Show member pathways
 12.82 IL2RA IL2 IFNA2 IFNA1 CXCL9 CTLA4
11
Pathways in cancer 36
12.76 IL2RB IL2RA IL2 IFNA2 IFNA1
12
Measles 36
Show member pathways
 12.76 IL2RB IL2RA IL2 IFNA2 IFNA1 CD28
13
NF-kappaB Signaling 4
12.55 TNFRSF8 TNFRSF1B IL2RB IL2RA IL2 IFNA1
14
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.34 IL2RB IL2RA IL2 CTLA4 CD28
15
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.29 IL2RB IL2RA IL2 IFNA2 IFNA1
16
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.96 IL2RB IL2RA IL2 IFNA2 CD28
17
Jak-Stat Signaling Pathway (sino) 66
11.85 IL2RB IL2RA IL2 IFNA2 IFNA1
18
Hematopoietic cell lineage 36
11.82 IL2RA CD7 CD1A
19
Innate Lymphoid Cell Differentiation Pathways 64
11.75 ITGAE IL2RB IL2RA IL2 CXCR3 CD7
20
Dendritic Cells Developmental Lineage Pathway 64
11.72 ITGAE IL2 IFNA2 CD1A
21
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.69 IL2 CXCL9 CCL22 CCL17
22
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.68 IL2RA IL2 CTLA4
23
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 11.66 TNFRSF1B IL2RB IL2RA IL2 CXCR3 CXCL9
24
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.62 IL2RB IL2RA IL2
25
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.58 IL2RB IL2RA IL2
26
T Cell Co-Signaling Pathway: Ligand-Receptor Interactions 64
11.55 TNFRSF8 CTLA4 CD28
27
Inflammatory Response Pathway 1
11.32 TNFRSF1B IL2RB IL2RA IL2 CD28
28
T-Cell Receptor and Co-stimulatory Signaling 1
11.25 IL2 CTLA4 CD28
29
IL12 signaling mediated by STAT4 1
11.19 IL2RA IL2 CD28
30
Telomere Extension by Telomerase 63
Show member pathways
 11.13 IL2RB IL2RA IL2
31
Th2 Differentiation Pathway 64
11.1 IL2RB IL2RA IL2 CD28 CCL22 CCL17
32
G-protein signaling_Rap2B regulation pathway 22
10.95 ITGAE IL2 CXCL9 CCL22 CCL17
Sources

GO Terms for Mycosis Fungoides

About this section

Cellular components related to Mycosis Fungoides according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.18 TNFRSF8 TNFRSF1B ITGAE IL2RB IL2RA DPP4
2 plasma membrane GO:0005886 10.13 TNFRSF8 TNFRSF1B ITGAE IL2RB IL2RA DPP4
3 integral component of plasma membrane GO:0005887 9.95 IL2RB CXCR3 CTLA4 CD28 CD1A CCR4
4 cell surface GO:0009986 9.73 IL2RB IL2RA DPP4 CXCR3 CD28 CCR10
5 external side of plasma membrane GO:0009897 9.32 ITGAE IL2RB IL2RA CXCR3 CXCL9 CTLA4
6 protein complex involved in cell adhesion GO:0098636 9.16 CTLA4 CD28
7 interleukin-2 receptor complex GO:0005893 8.96 IL2RB IL2RA

Biological processes related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.23 TNFRSF8 IL2RB IFNA1 CXCR3 CXCL9 CCR4
2 G protein-coupled receptor signaling pathway GO:0007186 10.14 IL2 CXCR3 CXCL9 CCR4 CCR10 CCL22
3 immune system process GO:0002376 10.03 IL2RA IL2 CTLA4 CD7 CD28 CD1A
4 adaptive immune response GO:0002250 9.93 IL2 IFNA2 IFNA1 CTLA4 CD7 CD1A
5 cell surface receptor signaling pathway GO:0007166 9.91 TNFRSF1B IL2RA IFNA2 CXCR3 CD28
6 inflammatory response GO:0006954 9.91 TNFRSF1B IFNA2 CXCR3 CXCL9 CCR4 CCL22
7 cell-cell signaling GO:0007267 9.88 IL2 IFNA2 CXCL9 CCL22 CCL17
8 positive regulation of cytosolic calcium ion concentration GO:0007204 9.84 IL2 CXCR3 CCR4 CCR10
9 cell chemotaxis GO:0060326 9.8 CXCR3 CCR4 CCR10 CCL22
10 chemotaxis GO:0006935 9.8 CXCR3 CXCL9 CCR4 CCR10 CCL22 CCL17
11 cytokine-mediated signaling pathway GO:0019221 9.8 TNFRSF1B IL2RB IL2RA IL2 IFNA2 IFNA1
12 neutrophil chemotaxis GO:0030593 9.79 CXCL9 CCL22 CCL17
13 calcium-mediated signaling GO:0019722 9.79 CXCR3 CCR4 CCR10
14 positive regulation of T cell proliferation GO:0042102 9.77 IL2RA IL2 CD28
15 humoral immune response GO:0006959 9.76 IFNA2 IFNA1 CD28
16 T cell costimulation GO:0031295 9.74 DPP4 CTLA4 CD28
17 T cell activation GO:0042110 9.72 DPP4 CD7 CD28
18 negative regulation of immune response GO:0050777 9.62 IL2RA CTLA4
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 IL2 CD28
20 regulation of T cell proliferation GO:0042129 9.61 TNFRSF1B CTLA4 CD28
21 negative regulation of lymphocyte proliferation GO:0050672 9.58 IL2RA IL2
22 interleukin-2-mediated signaling pathway GO:0038110 9.58 IL2RB IL2RA IL2
23 regulation of T cell homeostatic proliferation GO:0046013 9.52 IL2RA IL2
24 regulation of regulatory T cell differentiation GO:0045589 9.46 IL2RA IL2 CTLA4 CD28
25 immune response GO:0006955 9.44 TNFRSF1B IL2RA IL2 CXCR3 CXCL9 CTLA4
26 chemokine-mediated signaling pathway GO:0070098 9.43 CXCR3 CXCL9 CCR4 CCR10 CCL22 CCL17

Molecular functions related to Mycosis Fungoides according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.61 CXCL9 CCL22 CCL17
2 chemokine binding GO:0019956 9.5 CXCR3 CCR4 CCR10
3 type I interferon receptor binding GO:0005132 9.46 IFNA2 IFNA1
4 C-C chemokine binding GO:0019957 9.43 CXCR3 CCR4 CCR10
5 interleukin-2 binding GO:0019976 9.4 IL2RB IL2RA
6 interleukin-2 receptor activity GO:0004911 9.37 IL2RB IL2RA
7 C-C chemokine receptor activity GO:0016493 9.33 CXCR3 CCR4 CCR10
8 chemokine receptor activity GO:0004950 9.13 CXCR3 CCR4 CCR10
9 cytokine activity GO:0005125 9.1 IL2 IFNA2 IFNA1 CXCL9 CCL22 CCL17
Sources

Sources for Mycosis Fungoides

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....